Tag
A secondary analysis of the RACC trial reveals robot-assisted radical hysterectomy reduces intraoperative complications but shows similar postoperative morbidity and modest quality-of-life benefits compared with open surgery in early-stage
Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.
This retrospective study compares oncologic and perioperative outcomes of minimally invasive radical hysterectomy without uterine manipulator versus open radical hysterectomy in early-stage cervical cancer, showing comparable survival but i
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
The SENTIX study demonstrates that sentinel lymph node biopsy preserves quality of life, reduces lymphoedema incidence, and lowers early postoperative complications compared to pelvic lymphadenectomy in early-stage cervical cancer patients.
HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.
Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc
FAM19A4, SOX1, and PAX1 methylation assays demonstrate high diagnostic accuracy for identifying CIN3+ among non-16/18 hrHPV-positive women, outperforming cytology and reducing unnecessary colposcopies.
A mixed-methods study suggests pelvic exenteration offers meaningful long-term survival in selected patients with recurrent cervical cancer, while qualitative data reveal persistent physical, social, and sexual burdens that standardized qua
Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.
Introduction and Context Despite being highly preventable, cervical cancer remains a significant health threat. The...
The American College of Obstetricians and Gynecologists (ACOG) has qualifiedly endorsed the 2026 WPSI cervical cancer screening guidelines. This article details the core recommendations, highlights key updates including self-collection opti
This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu
A multi-database analysis reveals a significant decline in trachelectomy utilization since 2016. With comparable 10-year survival rates between trachelectomy and conization, clinical practice is rapidly shifting toward less radical, fertili
A large-scale meta-analysis reveals age-specific risks for cervical precancer in women living with HIV, justifying the WHO recommendation to initiate screening at age 25 with 3–5 year intervals to mitigate high recurrence and progression ra
Evidence suggests simple hysterectomy with pelvic lymphadenectomy may offer similar survival outcomes to radical hysterectomy in early-stage cervical cancer, with fewer adverse events and better short-term quality of life.
A 5-year follow-up study in El Salvador demonstrates that primary HPV screen-and-treat significantly reduces CIN2+ detection and HPV positivity compared to cytology, supporting extended screening intervals in low-resource settings.
A comprehensive 2025 systematic review informing the Canadian Task Force finds cytology remains effective into the 60s, HPV-based strategies detect more precursors but increase colposcopy and false positives, and self-sampling improves upta
The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.
A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.
